Randomized trial evaluates the efficacy of PARP inhibitors on progression free survival in ovarian cancer, suggesting potential treatment impacts depending on mutation types.
Preclinical studies have emphasized the potential connection between BRCA specific domains defects and the activity of Poly ADP-ribose polymerase inhibitors (PARPi). Nevertheless, real-world evidence regarding the impact of BRCA domain defects and mutations on PARPi efficacy are limited. The aim of his study was to evaluate the efficacy of PARPi in terms of progression free survival (PFS) according to BRCA domains defects and mutation types.
No takes yet. Share an insight, caveat, or question.
Buonaiuto et al. (2024) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: